PeptideLabs Logo
PeptideLabs
All profiles

NAD+

Cofactor · Other substances

Not a peptide. An endogenous cofactor; wellness and anti-ageing claims do not equal approved efficacy.

Not a peptide medicine
LibraryNo account · this device only

Also known as: Nicotinamide adenine dinucleotide · NAD

Use at a glance

NAD+

Not a peptide. An endogenous cofactor; wellness and anti-ageing claims do not equal approved efficacy.

Which entry would you like to view?

Choose a source entry. Different products and study groups do not form one combined plan.

Online report · not medically verified

What amount?
50–100 mg
How often?
2–3 times per week
What time of day?
not reliably established
In what setting?
Community subcutaneous reports
How is it used?
A supplement, a substance found in the body and a medicine are not equivalent. Form and intended use matter.
Does it need mixing?
Not universally. Ready-made solutions, tablets and raw powders differ. Water does not turn raw material into a sterile medicine.
View preparationCheck sources
Overview of all entries

  • NAD+ · Community subcutaneous reports

    Online report · not medically verified

    50–100 mg · 2–3 times per week · not reliably established

  • NAD+ · Community intramuscular reports

    Online report · not medically verified

    50–100 mg · 1–3 times per week · not reliably established

  • NAD+ · Clinic IV reports

    Online report · not medically verified

    250–1,000 mg · not reliably established · Time of day not stated here

More factsCofactor · Other substances
Classification
Cofactor · Other substances
Research focus
Not a peptide. An endogenous cofactor; wellness and anti-ageing claims do not equal approved efficacy.
Evidence
Early human data
Status
Not a peptide medicine

This entry is not a single peptide, or its use depends on diagnosis, product form or composition. A blanket peptide dose would be misleading.

Schedule explained in detailNo uniform peptide protocol

Amount status

Community source: subcutaneous 50–100 mg two to three times weekly, intramuscular 50–100 mg one to three times weekly; clinic IV claims of 250–1,000 mg. No approved wellness dose.

Profile evidence level: early_human.

Timing

Route and infusion rate substantially change tolerability; IV is not for self-administration.

No individual recommendation.

Cycle/duration

No clinically validated anti-aging cycle; small ongoing studies and community plans are not equivalent.

No individual recommendation.

External community reference availableThe external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

External community reference available

The external page is used only to document community claims. Advertising and affiliate material were excluded; its content is neither approval nor proof of quality.

Open community source

Mixing & calculations

Not universally. Ready-made solutions, tablets and raw powders differ. Water does not turn raw material into a sterile medicine.

See calculation examplesFollow sample figures to understand mg, ml and scale markings.

Documented vial and fluid examples

The table shows only the arithmetic for explicitly stated inputs. It confirms neither vial content nor stability, sterility or an appropriate target amount.

500 mg · assumed final volume: 5 ml

Community calculation example
Calculated amount25 mg
Concentration100,000 µg/ml
U-10025 U
Volume0.25 ml
Calculated amount50 mg
Concentration100,000 µg/ml
U-10050 U
Volume0.5 ml
Calculated amount100 mg
Concentration100,000 µg/ml
U-100100 U
Volume1 ml

500 mg · assumed final volume: 2.5 ml

Community calculation example
Calculated amount50 mg
Concentration200,000 µg/ml
U-10025 U
Volume0.25 ml
Calculated amount100 mg
Concentration200,000 µg/ml
U-10050 U
Volume0.5 ml
All preparation informationProduct details and calculation examples from the available sources.

Community arithmetic: 500 mg +5 ml =100 mg/ml; 25 mg =25 U, 50 mg =50 U, 100 mg =100 U. At +2.5 ml =200 mg/ml, 50 mg would be =25 U. Not transferable to buffered or differently formulated products.

Reconstitution & quantitiesOpen basics, units and sources
Explained in very simple termsBefore reading any number: this page reports what a product label, study or online community states. It does not say what any person should use.

Amount

mg or µg describe the mass of a substance. That is not the same as ml of fluid or U on a syringe. The number is only the amount stated by the identified source.

Interval

The interval only describes the time stated between two points. For example, once every 7 days does not mean daily and never justifies catching up or doubling.

Cycle

A cycle is a stated period that may include breaks. A community cycle proves neither effectiveness nor safety and does not prevent long-term risks.

Reconstitution

Reconstitution means mixing powder with a defined volume of fluid. This changes concentration, not the total amount in the vial. On U-100, 100 U equals exactly 1 ml of volume.

Not a guide to misuse

All community figures are shown only to place widely circulated online protocols in context. They are not instructions for self-use, injection, performance enhancement or any other misuse. Approved figures apply only to the exact named product, approved indication and medical supervision.

Research, risks & more detailsMechanism, adverse effects, storage, comparisons and common questions.

Mechanism: what is supported and what does not follow

Endogenous redox cofactor involved in cellular energy metabolism

NAD+ is classified as “Endogenous redox cofactor involved in cellular energy metabolism”. Not a peptide. An endogenous cofactor; wellness and anti-ageing claims do not equal approved efficacy. This describes the investigated pathway but does not validate a community use, amount, route or combination.

01

Redox cofactor biology

This concerns substances acting as helper molecules in cellular energy and repair reactions, similar to a tool that supports many different chemical reactions. Enzyme activity and cell energy markers are measured in the lab.

02

Cellular energy metabolism

Researchers study how cells produce and use energy, particularly through the mitochondria, similar to measuring how efficiently an engine burns fuel. Typical measures include oxygen consumption and energy output in cell models.

03

Fatty acid transport

This studies how substances support the transport of fatty acids into and out of cells, similar to a delivery service bringing fat to the mitochondria where it is burned. Fat metabolism markers are measured in lab and animal models.

What communities discuss

These themes describe discussions and vendor claims. They do not prove benefit, safety, product identity or suitable use.

Biohacker and longevity forums

Users compare self-assembled combinations of peptides aimed at influencing ageing processes or energy levels, often based on blood tests or subjective wellbeing scales. Personal self-experiments and marketing promises do not replace controlled long-term human studies.

Anti-aging forums

Combinations of growth-axis, mitochondrial, and skin peptides are compared here with the goal of influencing visible or felt signs of ageing, often documented personally over years. Anecdotes and vendor advertising about slowed ageing are not scientific proof.

Energy and fatigue anecdotes

Subjectively perceived increases in energy after using mitochondrial peptides or vitamin injections are reported, often based on personal daily-energy ratings. Such impressions are strongly influenced by placebo effects.

Adverse effects and safety risks

  • Risks depend particularly on actual identity, dosage form, concentration, excipients and medical rationale. Vitamins, cofactors and diluents can also cause adverse effects or interactions.
  • Local reaction, infection, abscess and contamination are possible with any injection that is not professionally manufactured and administered.
  • A label or clear appearance does not exclude unknown purity, wrong identity, endotoxins or concentration errors.

Do not self-use / obtain clinical review

  • Allergy, kidney/liver disease, pregnancy, relevant medicines, and absent diagnosis or product identity must be resolved before use.
  • Acute symptoms, allergic reaction, breathing difficulty, chest pain, neurological deficits or severe abdominal pain require immediate medical care.
  • Children and adolescents, pregnancy/breastfeeding, and people with relevant disease should not be part of unsupervised experiments.

Monitoring and laboratory markers

  • Monitoring follows the specific medical purpose, such as confirming deficiency, organ function or tolerability. A blanket peptide lab panel is not meaningful.
  • Baseline, objective, measurement timing and stop criteria must be defined professionally in advance. Individual laboratory values cannot compensate for unknown product quality.

Evidence boundary

Early human data

Wellness and anti-ageing claims do not equal approved efficacy.

Clinical evidence

Some early, usually small human studies or observations exist, but they do not yet count as robust proof of efficacy.

NAD+ is not a peptide but an endogenous redox cofactor, unlike peptide-based mitochondrial candidates such as MOTS-c.

Storage and stability

  • The manufacturer label and prescribing information take priority. Storage instructions from a different product do not transfer.
  • Unapproved vials often lack dependable stability data before and after mixing; ‘2–8 °C’ or ‘28 days’ is not a universal standard.
  • Do not use after seal damage, particles, cloudiness, discoloration, unknown date or interrupted cold chain. Visual inspection does not prove sterility.

Troubleshooting and common errors

  • U-100 units measure volume, not drug amount: 100 U equals 1 mL. A wrong concentration makes every unit figure wrong.
  • Do not shake or dilute further to ‘fix’ cloudiness, particles or uncertain solubility; discard and obtain professional clarification.
  • Do not calculate a double or extra amount to compensate for missed use or an uncertain injection.
  • Without a COA, clear supplier, correct label and consistent vial information, identity is not confirmed.

Regulatory status and WADA

Not a peptide medicine

This is not a standalone peptide active; product form and regulatory status need separate consideration.

WADA 2026

The atlas has no explicit WADA flag for this profile. That does not automatically mean every form, route or related class is permitted in sport.

WADA — 2026 Prohibited List

Combinations / stacks

  • Combinations change effects, adverse effects and laboratory values; evidence for one substance does not establish the safety of a stack.
  • Overlapping pathways may add up. Hormonal, glucose, blood-pressure, coagulation, immune and sedating effects are important potential interactions.
  • Non-standardised blends prevent separate dosing, cause attribution and dependable reconstitution.

Frequently asked questions

Is an amount shown here a recommendation?

No. This page separates approved product information, study protocols and community information. No number or calculator is an individual dosing recommendation.

Does the U-100 calculator prove correct use?

No. It only converts mass, volume and syringe scale. It cannot check identity, purity, sterility, stability, solvent or medical suitability.

Can this profile be combined with other substances?

Safety of a combination cannot be inferred from a single-substance profile. Overlapping pathways, medicines and undefined blends can increase risk.

Which source controls when information conflicts?

For approved medicines, the current prescribing information and treating professional control. For research substances, conflict shows that no dependable self-use standard exists.

Are community claims clinical evidence?

No. Anecdotes can generate questions but do not replace controlled studies, regulatory review, or identity and quality testing.

Back to all 64 profilesOpen scientific atlas profile